Glucagon: A Checklist Guide to Its Peptide Product Composition
Title: Glucagon: A Checklist Guide to Its Peptide Product Composition Abstract: Glucagon, a 29-amino-acid peptide hormone, is critical in glucose homeostasis and emergency hypoglycemia management. This guide analyzes its product composition, comparing key brands (e.g., Eli Lilly, Novo Nordisk, Xeris) across purity (>98% by HPLC), stability (lyophilized vs. liquid formulations), and delivery systems (auto-injectors vs. nasal powder). Market trends indicate a 7.8% CAGR (2023–2030), driven by diabetes and obesity applications. Technical trade-offs include synthetic vs. recombinant production; recombinant offers higher batch consistency but higher cost. Product certifications (FDA, EMA, GMP) are essential for quality assurance. Selection criteria prioritize shelf life (24–36 months), cold-chain logistics (2–8°C), and excipient compatibility. Industry data shows glucagon’s expanding role in cardiac and metabolic research, with over 15 approved variants globally. This checklist aids buyers in navigating regulatory, technical, and supply-chain complexities.